Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM120 in healthy adults
NCT03392116Phase 1Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NGM120 in cachexia (4 arms), sponsored by NGM Biopharmaceuticals. Primary endpoint: Treatment Emergent Adverse events at 84 days. Started Jan 2018; status: completed.
02
Drugs
NGM120
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT03392116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392116.